









Markets
/
Stocks
/
nasdaq-maze
/

Maze Therapeutics Inc

MAZE

45.030USD

+1.080+2.46%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

2.16BMarket Cap

LossP/E TTM



Maze Therapeutics Inc

45.030

+1.080+2.46%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Maze Therapeutics Inc

Currency: USD Updated: 2026-02-06

Key Insights

Maze Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 19 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 49.12.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Maze Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

19 / 392

Overall Ranking

109 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Maze Therapeutics Inc Highlights

StrengthsRisks

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Undervalued

The company’s latest PE is -17.60, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 41.80M shares, increasing 4.44% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 1.93K shares of this stock.

Analyst Rating

Based on 10 analysts

Strong Buy

Current Rating

49.125

Target Price

+11.77%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Maze Therapeutics Inc is 7.84, ranking 75 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 1139.68%.

Score

Industry at a Glance

Previous score

7.84

Change



Financials

9.47

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.03

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.57

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Maze Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Maze Therapeutics Inc is 6.70, ranking 236 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -17.60, which is -1265.19% below the recent high of 205.07 and -6.91% above the recent low of -18.81.

Score

Industry at a Glance

Previous score

6.70

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 19/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Maze Therapeutics Inc is 9.11, ranking 13 out of 392 in the Biotechnology & Medical Research industry. The average price target is 39.50, with a high of 60.00 and a low of 34.00.

Score

Industry at a Glance

Previous score

9.11

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 10 analysts

Strong Buy

Current Rating

49.125

Target Price

+2.05%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Maze Therapeutics Inc

MAZE

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Maze Therapeutics Inc is 9.04, ranking 42 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 50.19 and the support level at 38.94, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.56

Change

1.48

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.010

Neutral

RSI(14)

54.421

Neutral

STOCH(KDJ)(9,3,3)

47.585

Sell

ATR(14)

3.584

Low Volatility

CCI(14)

-20.700

Neutral

Williams %R

39.717

Buy

TRIX(12,20)

0.579

Sell

StochRSI(14)

19.553

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

46.324

Sell

MA10

45.348

Sell

MA20

43.779

Buy

MA50

41.507

Buy

MA100

35.439

Buy

MA200

24.330

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Maze Therapeutics Inc is 7.00, ranking 86 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 86.88%, representing a quarter-over-quarter increase of 3.95%. The largest institutional shareholder is The Vanguard, holding a total of 1.70M shares, representing 3.53% of shares outstanding, with 131.73% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Third Rock Ventures, LLC

5.42M

-22.78%

Frazier Life Sciences Management, L.P.

4.57M

-0.00%

ARCH Venture Partners

4.12M

Deep Track Capital LP

3.95M

Alphabet, Inc.

2.41M

Andreessen Horowitz

1.70M

The Vanguard Group, Inc.

Star Investors

1.33M

+218.14%

Matrix Capital Management Company, LP

1.65M

-33.49%

VR Adviser, LLC

1.23M

Logos Global Management LP

1.23M

+100.57%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Maze Therapeutics Inc is 5.31, ranking 48 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.